NCT06621212View on ClinicalTrials.gov

Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML

PHASE2RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

July 5, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Relapsed/Refractory Acute Myeloid LeukaemiaMyeloid Malignancy
Interventions
DRUG

mitoxantrone hydrochloride liposome

Mitoxantrone hydrochloride liposome (30 mg/m\^2) on day 1, every 4 weeks

DRUG

Cytarabine

Cytarabine (100 mg/m\^2 ) on day 1-7, every 4 weeks

DRUG

Venetoclax

Venetoclax 100 mg on day 2，200 mg on day 3，400 mg on day 4-8, every 4 weeks

Trial Locations (1)

310003

RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
collaborator

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

INDUSTRY

lead

First Affiliated Hospital of Zhejiang University

OTHER